Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment

Bin Li,1 Zhongyin Jiang,1 Diya Xie,1 Yiqing Wang,1 Xingzhen Lao2 1Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, Jiangsu Province 210093, China; 2Department of Microbial and Biochemical Pharmacy, School of Life Science and Technology,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li B, Jiang Z, Xie D, Wang Y, Lao X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	photothermal therapy nanoparticles Accumulation in tumor Cetuximab EGFR Anti-angiogenesis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a5164026982d4aaf8289ba99fcb873be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5164026982d4aaf8289ba99fcb873be
record_format	dspace
spelling	oai:doaj.org-article:a5164026982d4aaf8289ba99fcb873be2021-12-02T07:24:27ZCetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment1178-2013https://doaj.org/article/a5164026982d4aaf8289ba99fcb873be2018-11-01T00:00:00Zhttps://www.dovepress.com/cetuximab-modified-cus-nanoparticles-integrating-near-infrared-ii-resp-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Bin Li,1 Zhongyin Jiang,1 Diya Xie,1 Yiqing Wang,1 Xingzhen Lao2 1Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, Jiangsu Province 210093, China; 2Department of Microbial and Biochemical Pharmacy, School of Life Science and Technology, China Pharmaceutical University, Nanjing , Jiangsu Province 210009, China Background: Photothermal therapy (PTT) has received extensive attention owing to its non-invasive nature and highly therapeutic outcomes. PTT agents and near-infrared (NIR) laser are essential elements in PTT. However, most PTT agents are composed of heavy metals, characterized by serious cytotoxicity and side effects, and NIR irradiation often damages normal tissue owing to the high dose, thus limiting the clinical application of PTT. Purpose: In this regard, exploring new perspectives enabling more PTT agents to be enriched into the tumor and NIR laser irradiation decay in PTT is vital. Methods: In this study, cetuximab (Ab), an anti-angiogenic antibody which targets the EGFR, was modified on CuS NPs (CuS-Ab NPs) to improve the aggregation of CuS NPs in the tumor. Results: The cellular uptake data and the biodistribution results showed comparable accumulation of CuS-Ab NPs in tumor, thus decreasing the cytotoxicity and side effects in normal tissues. More importantly, the modification of Ab in CuS-Ab NPs impressively inhibited the formation and progression of tumor vessels, as demonstrated by immunohistochemistry staining. The introduction of anti-vessel treatment requires CuS-Ab NPs to provide weak PTT, which means that a small amount of laser energy is required, inevitably causing negligible damage to normal tissue. Conclusion: Therefore, our tailor-made CuS-Ab NPs have promising potential in clinical applications. Keywords: photothermal therapy, CuS NPs, active targeting, cetuximab, EGFR, anti-angiogenesisLi BJiang ZXie DWang YLao XDove Medical Pressarticlephotothermal therapynanoparticlesAccumulation in tumorCetuximabEGFRAnti-angiogenesisMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 7289-7302 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	photothermal therapy nanoparticles Accumulation in tumor Cetuximab EGFR Anti-angiogenesis Medicine (General) R5-920
spellingShingle	photothermal therapy nanoparticles Accumulation in tumor Cetuximab EGFR Anti-angiogenesis Medicine (General) R5-920 Li B Jiang Z Xie D Wang Y Lao X Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
description	Bin Li,1 Zhongyin Jiang,1 Diya Xie,1 Yiqing Wang,1 Xingzhen Lao2 1Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, Jiangsu Province 210093, China; 2Department of Microbial and Biochemical Pharmacy, School of Life Science and Technology, China Pharmaceutical University, Nanjing , Jiangsu Province 210009, China Background: Photothermal therapy (PTT) has received extensive attention owing to its non-invasive nature and highly therapeutic outcomes. PTT agents and near-infrared (NIR) laser are essential elements in PTT. However, most PTT agents are composed of heavy metals, characterized by serious cytotoxicity and side effects, and NIR irradiation often damages normal tissue owing to the high dose, thus limiting the clinical application of PTT. Purpose: In this regard, exploring new perspectives enabling more PTT agents to be enriched into the tumor and NIR laser irradiation decay in PTT is vital. Methods: In this study, cetuximab (Ab), an anti-angiogenic antibody which targets the EGFR, was modified on CuS NPs (CuS-Ab NPs) to improve the aggregation of CuS NPs in the tumor. Results: The cellular uptake data and the biodistribution results showed comparable accumulation of CuS-Ab NPs in tumor, thus decreasing the cytotoxicity and side effects in normal tissues. More importantly, the modification of Ab in CuS-Ab NPs impressively inhibited the formation and progression of tumor vessels, as demonstrated by immunohistochemistry staining. The introduction of anti-vessel treatment requires CuS-Ab NPs to provide weak PTT, which means that a small amount of laser energy is required, inevitably causing negligible damage to normal tissue. Conclusion: Therefore, our tailor-made CuS-Ab NPs have promising potential in clinical applications. Keywords: photothermal therapy, CuS NPs, active targeting, cetuximab, EGFR, anti-angiogenesis
format	article
author	Li B Jiang Z Xie D Wang Y Lao X
author_facet	Li B Jiang Z Xie D Wang Y Lao X
author_sort	Li B
title	Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
title_short	Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
title_full	Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
title_fullStr	Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
title_full_unstemmed	Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
title_sort	cetuximab-modified cus nanoparticles integrating near-infrared-ii-responsive photothermal therapy and anti-vessel treatment
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/a5164026982d4aaf8289ba99fcb873be
work_keys_str_mv	AT lib cetuximabmodifiedcusnanoparticlesintegratingnearinfrarediiresponsivephotothermaltherapyandantivesseltreatment AT jiangz cetuximabmodifiedcusnanoparticlesintegratingnearinfrarediiresponsivephotothermaltherapyandantivesseltreatment AT xied cetuximabmodifiedcusnanoparticlesintegratingnearinfrarediiresponsivephotothermaltherapyandantivesseltreatment AT wangy cetuximabmodifiedcusnanoparticlesintegratingnearinfrarediiresponsivephotothermaltherapyandantivesseltreatment AT laox cetuximabmodifiedcusnanoparticlesintegratingnearinfrarediiresponsivephotothermaltherapyandantivesseltreatment
_version_	1718399469858324480

Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment

Ejemplares similares